Results 131 to 140 of about 11,226 (207)

Nanobodies: A Promising Toolkit for Diagnostic Applications

SmartMat, Volume 7, Issue 3, June 2026.
This review focuses on camelid‐derived nanobodies (VHHs) and explains how their small size and high stability support robust diagnostic design. Applications across ELISA, lateral flow assays, and PET/SPECT imaging are summarized, along with clinical progress such as caplacizumab.
Wei Wu, Abid Ali, Li Sun, Jiahao Hu, Lina Hameed, Saba Shafi, Ali Raza, Khuzin Dinislam, Wenjing Xing, Long Rong, Jie Lin, Jian Ma   +11 more
wiley   +1 more source

Daratumumab plus bortezomib and dexamethasone (Dara‐VD) in newly diagnosed Mayo 2004 stage IIIA and IIIB light‐chain amyloidosis: Long‐term follow‐up results from a prospective phase 2 study

British Journal of Haematology, Volume 208, Issue 6, Page 2096-2103, June 2026.
Summary Anti‐CD38 monoclonal antibodies dramatically improve the prognosis in immunoglobulin light‐chain (AL) amyloidosis, yet patients with end‐stage (Mayo 2004 IIIB) disease are typically excluded from prospective trials. To evaluate the daratumumab plus bortezomib and dexamethasone (Dara‐VD) regimen in Mayo 2004 stage III patients, we conducted a ...
Gao Xue‐min, Xu Chengyang, Gao Ya‐juan, Guan Ai, Xu Yi, Chang Long, Shen Kai‐ni, Li Jian   +7 more
wiley   +1 more source

MRD‐negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD‐positive after first‐line therapy: Final analysis of the open‐label, single‐arm multicentric phase 2 trial DART4MM

British Journal of Haematology, Volume 208, Issue 6, Page 2069-2078, June 2026.
In newly diagnosed multiple myeloma patients in ≥Very Good Partial Remission (VGPR) after a first‐line therapy daratumumab as consolidation/maintenance improved long‐term minimal residual disease negativity. Summary Daratumumab is approved for front‐line and relapsed myeloma therapy.
Alessandro Gozzetti, Paola Pacelli, Federico Caroni, Donatella Raspadori, Elena Bestoso, Elisabetta Antonioli, Gabriele Buda, Sara Ciofini, Adele Santoni, Luca Puccetti, Francesca Bacchiarri, Ludovica Pengue, Dania Tocci, Irene Attucci, Maria Livia del Giudice, Miriana Ruggieri, Alessandra Lombardo, Anna Marina Liberati, Veronica Candi, Vincenzo Sammartano, Alessandra Cartocci, Anna Sicuranza, Sara Galimberti, Alessandro Maria Vannucchi, Monica Bocchia   +24 more
wiley   +1 more source

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model

eJHaem
Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab therapy.
Niels vanNieuwenhuijzen, Marta Cuenca, Leonie Abbink, Margot Jak, Victor Peperzak, Monique C. Minnema   +5 more
doaj   +1 more source

Biochemical bone biomarkers in plasma cell dyscrasias

British Journal of Haematology, Volume 208, Issue 6, Page 1909-1923, June 2026.
Visual abstract depicting that bone turnover markers reflect dynamic alterations in bone remodelling across the spectrum of plasma cell dyscrasias but remain limited by assay variability, biological confounding and incomplete integration with imaging and risk stratification.
Guido Nador, Rohit Vijjhalwar, Muhammad Kassim Javaid, Claire M. Edwards, Karthik Ramasamy   +4 more
wiley   +1 more source

Functional high‐risk phenotype predicts poor survival in multiple myeloma independent of front‐line treatment: A secondary analysis of CIBMTR data

British Journal of Haematology, Volume 208, Issue 6, Page 2134-2142, June 2026.
Summary Functional high‐risk (FHR) multiple myeloma (FHRMM) is often defined as progression within 12–24 months of front‐line autologous hematopoietic stem cell transplantation (AHSCT). For patients with early progression after suboptimal front‐line therapies, it is challenging to assign the disease progression to a true FHR phenotype versus less ...
Utkarsh Goel, Catalin Dragomirescu, Saurabh Zanwar, Rafaella Cassano Cassano, Kara I. Cicero, Andrew J. Cowan, Rahul Banerjee, Faiz Anwer, Jack Khouri, Danai Dima   +9 more
wiley   +1 more source

P183 | DELAYED DARATUMUMAB ADDITION TO LENALIDOMIDE-DEXAMETHASONE IN OLDER MULTIPLE MYELOMA PATIENTS: INSIGHTS FROM REAL-WORLD DATA

Haematologica
Introduction In patients (pts) with multiple myeloma (MM), the combination of daratumumab, lenalidomide, and dexamethasone (Dara-Rd) is a standard of care, approved both for frontline treatment of non-transplant eligible (NTE) pts and in the relapsed ...
L. Cani, A. Di Nicola, A. Evangelista, I. Delle Donne, G. Bertuglia, A. Casson, M. D’agostino, F. Gay, A. Larocca, E. Marchetti, R. Mina, S. Oliva, T. Picardi, B. Bruno, S. Bringhen, G. Benevolo   +15 more
doaj  

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, Volume 116, Issue 6, Page 697-708, June 2026.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

European Journal of Haematology, Volume 116, Issue 6, Page 928-936, June 2026.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso, S. Masci, M. Talarico, A. Vitale, S. Barbato, V. Solli, M. Puppi, I. Rizzello, L. Pantani, P. Tacchetti, M. Iezza, R. Restuccia, I. Sacchetti, E. Manzato, S. Ghibellini, S. Armuzzi, B. Taurisano, M. Cavo, E. Zamagni   +18 more
wiley   +1 more source

Late Presentation of de Novo Proliferative Glomerulonephritis With Monoclonal IgG Deposits in a Renal Allograft: A Rare Case With an Unusual Clinical Course

Nephrology, Volume 31, Issue 6, June 2026.
ABSTRACT Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is a form of monoclonal gammopathy of renal significance (MGRS) in which monoclonal immunoglobulin deposits are found within the glomerulus, without involvement of other renal compartments.
Hayley J. Duxbury, David A. Brown, Adrian Y. S. Lee, Germaine Wong, Fiona Kwok, Seethalakshmi Viswanathan   +5 more
wiley   +1 more source